In our previous work, using an immunohistochemical approach with gastric carcinoma tissue, we found that the expression of PAR1, along with a metalloproteinase known to activate PAR1 (MMP1) was associated with poorer prognosis, compared with expression-negative tumors [22]. This evidence concerns the gene F2R and gastric carcinoma.